BC

Blood Cancer Journal

Blood Cancer Journal is a peer-reviewed fully open access journal dedicated to publishing articles related to hematologic malignancies and related disorders.

Looking to publish in Blood Cancer Journal? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.

Existing customer login
Subject Hematology, Oncology
Impact Factor 11.6
Quartile Q1
Open Access Type Open
ISSN 2044-5385
eISSN 2044-5385
Invitation Only No
Cost Range Original Research: £3690.00/$5490.00/€4390.00; Letter / Correspondence / Comment: £1215.00/$1675.00/€1515.00, subject to VAT or local taxes where applicable.

Submission Instructions

Blood Cancer Journal accepts the following article types. Click on an article type to view submission instructions.

Article

Cover Letter A cover letter is required. The cover letter must provide the corresponding author's affiliation and contact information, explain the importance of the work and its suitability for the journal's readership, confirm originality and that the work has not been previously published or submitted elsewhere, include a Competing Interests statement, and include prior reviewer comments if the manuscript was previously considered by another journal.
Abstract An abstract is required. The abstract must be unstructured and no more than 200 words. The abstract must be unstructured.
Manuscript The main text must not exceed 4,500 words, excluding the abstract, tables/figures, and references. The manuscript must include a Materials/Subjects and Methods section with enough detail and references to allow reproduction of experimental procedures. The manuscript must include an Author Contributions statement, a Competing Interests statement before the References section, documentation of any large language model use in the Methods section or a suitable alternative section, and a Data Availability Statement.
References The submission may include a maximum of 60 references. References must follow Vancouver format. References must be numbered in order of citation and listed in numerical order at the end of the paper, with all authors listed for works with up to six authors and only the first six followed by et al. for works with more than six authors.
Figures & Tables The submission may include a maximum of 8 tables or figures. Figures must be uploaded as separate files rather than embedded in the text, and each table must be uploaded separately. Tables must be editable and figure legends must appear on a separate manuscript page after the References section.
Reformat to Blood Cancer Journal using Livewrite Premium

Review Article

Cover Letter A cover letter is required and must include the corresponding author's affiliation and contact information, a brief explanation of the work's importance and fit for the journal's readership, confirmation that the material is original research, has not been previously published, is not under consideration elsewhere, and a Competing Interests statement. Cover letter must include the corresponding author's affiliation and contact information, explain the importance of the work and its suitability for the journal's readership, confirm originality, confirm that it has not been previously published or submitted elsewhere, and include a Competing Interests statement.
Abstract An abstract is required for Review Articles. The abstract must be unstructured and must not exceed 300 words. The abstract must be unstructured. No mandatory headings are specified for the abstract.
Manuscript The main text must not exceed 5,000 words, excluding the abstract, tables/figures, and references. Use of a large language model must be documented in the Methods section or a suitable alternative part of the manuscript if a Methods section is not available.
References Review Articles may include a maximum of 100 references. References must follow the Vancouver format. References must be cited in text as numbered citations starting at one and listed at the end in numerical order of citation, with up to six authors listed in full and more than six abbreviated after the first six with et al.
Figures & Tables Review Articles may include a maximum of 8 tables or figures. Figures must not be embedded within the text and must be uploaded as separate files, and each table must be uploaded separately. Composite figures containing more than three individual figures count as two figures, and tables must be editable.
Reformat to Blood Cancer Journal using Livewrite Premium

Current Treatment Algorithm

Cover Letter A cover letter is required. Cover letter must provide the corresponding author's affiliation and contact information, explain the work's importance and suitability for the readership, confirm originality and that it has not been published or submitted elsewhere, include any previous reviewer comments if applicable, and include a competing interests statement.
Abstract An abstract is required. Abstract must be unstructured and no more than 200 words. Abstract must be unstructured. No mandatory headings are specified for the abstract.
Manuscript Main text must not exceed 3,000 words excluding the abstract, tables/figures, and references. The manuscript must document any use of a large language model in the Methods section or another suitable section if no Methods section is available, and it must include an Author Contributions statement and a Competing Interests statement.
References Submissions may include a maximum of 100 references. References must follow Vancouver format. References must be cited in numerical order in the text and listed in matching numerical order at the end, with all authors listed for up to six authors and the first six followed by et al. for more than six authors.
Figures & Tables Submissions may include a maximum of 5 tables or figures. Figures must not be embedded in the text and must be uploaded as separate files, and each table must be uploaded as a separate file. Composite figures containing more than three individual figures count as two figures, and tables must be editable.
Reformat to Blood Cancer Journal using Livewrite Premium

Correspondence

Cover Letter Cover letter is required. Cover letter must include the corresponding author's affiliation and contact information, briefly explain the importance of the work and its suitability for the journal's readership, confirm originality and that the material has not been previously published or submitted elsewhere, and include a Competing Interests statement.
Abstract Abstract is not required.
Manuscript Main text must not exceed 1,500 words, excluding tables, figures, and references. Manuscript must document any use of a large language model in the Methods section or a suitable alternative section if no Methods section is available.
References References are limited to a maximum of 15. References must follow Vancouver format. References must be cited in the text as numbers starting at one and listed at the end in numerical order of citation, listing all authors for up to six authors and the first six followed by et al. for more than six authors.
Figures & Tables Submissions may include a maximum of 2 tables or figures. Figures must not be embedded within the text and must be uploaded as separate files. Figure legends must appear on a separate manuscript page after the References section, and each table must be uploaded as a separate editable file with a title or caption and clear sequential labeling.
Reformat to Blood Cancer Journal using Livewrite Premium

Recent Publications

Bridging therapy response and type as determinants of cilta-cel outcomes in relapsed/refractory multiple myeloma

Doris K. Hansen, Brett M. Reid, Ariel Grajales-Cruz, Peter Cheng, Zhuoer Xie, Brandon Blue, Dae Hyun Lee, Laura Oswald, Gabriel De Avila, David Scheiber-Camoretti, Ken Harada, Daniel De Avila, Brandon Kale, Karla Feliciano Salva, David Kaldas, Kristy Matte, Todd Stinard, Rebecca Gonzalez, Victoria Alegria, Matthew Perciavalle, Helen Pai, Mukta Sharma, Kevin C. De Braganca, Zaina P. Qureshi, Fabiana Perna, Hien Liu, Kenneth H. Shain, Rachid Baz, Taiga Nishihori, Melissa Alsina, Ciara L. Freeman, Omar Alexis Castaneda Puglianini, Frederick L. Locke, Lauren C. Peres

10.1038/s41408-026-01633-5
View Publication

Early post-transplant molecular residual disease predicts outcomes in myelodysplastic neoplasms/syndromes and acute myeloid leukemia undergoing allogeneic transplantation

Wan-Hsuan Lee, Xavier Cheng-Hong Tsai, Chien-Chin Lin, Feng-Ming Tien, Min-Yen Lo, Yu-Sung Chang, Tai-Chung Tseng, Tai-Chung Huang, Bor-Sheng Ko, Ming Yao, Yen-Ling Peng, Mei-Hsuan Tseng, Yuan-Yeh Kuo, Ming-Chih Liu, Szu-Hwei Lee, Chi-Yuan Yao, Chang-Tsu Yuan, Shan-Chi Yu, Hwei-Fang Tien, Hsin-An Hou, Wen-Chien Chou

10.1038/s41408-026-01637-1
View Publication

Infection risk and management in patients with relapsed/refractory multiple myeloma treated with linvoseltamab in the LINKER-MM1 study

Joshua Richter, Madhav Dhodapkar, Mansi R. Shah, Joaquín Martinez-Lopez, Mina Awad, C. Akunna Otele, Mengying Li, Christian Hampp, Wenying Deng, Katherine Knorr, Tito Roccia, Glenn S. Kroog, Paula Rodríguez-Otero

10.1038/s41408-026-01636-2
View Publication

Redefining the role of second transplantation in adult ALL with post-transplant relapse in the modern era of immuno-targeted therapies

Jaehyun Ahn, Daehun Kwag, Gi June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Chang-Ki Min, Seok-Goo Cho, Jae-Ho Yoon

10.1038/s41408-026-01628-2
View Publication

Real-world treatment patterns and outcomes of brentuximab vedotin–based therapy in CD30-positive lymphomas in China: the prospective BRAVE study

Ming-Ci Cai, Ou Bai, Hui-Lai Zhang, Chuan-Xu Liu, Wen-Yang Huang, Li-Hong Liu, Zeng-Jun Li, Lu-Qun Wang, Li-Ping Su, Wei Zhang, Wei Xu, Kai-Yang Ding, Guo-Hui Cui, Hong-Mei Jing, Hua-Qing Wang, Zheng Ge, Fang Zhu, Fei Li, Xiao-Bo Wang, Shen-Miao Yang, Bing Xu, Ying Lu, Yu-Fu Li, Ting Niu, Ke-Qian Shi, Cai-Xia Li, Zhen-Qian Huang, Hong Liu, Ling Qin, Shao-Jie Wu, Hong-Yu Zhang, Jian-Li Wang, Wen-Xin Zhang, Wei-Li Zhao

10.1038/s41408-026-01627-3
View Publication

Frequently asked questions

How long does it take to publish?

Reviewers are given 14 days from acceptance to submit their reports. Revision requests are used when authors can address concerns in six months or less. Accepted articles are published immediately as an Article in Press. Proof corrections must be returned within 48 hours of receipt.

Reformat to Blood Cancer Journal using Livewrite Premium

Is a cover letter required?

A cover letter is required. It should include the corresponding author's affiliation and contact information, explain the importance of the work and its suitability for the journal's readership, confirm originality and exclusive submission, include previous reviewer comments if the manuscript was considered elsewhere, and include a Competing Interests statement.

Reformat to Blood Cancer Journal using Livewrite Premium

What are the publication costs?

An article processing charge is required. Original Research: £3690.00/$5490.00/€4390.00; Letter / Correspondence / Comment: £1215.00/$1675.00/€1515.00, subject to VAT or local taxes where applicable.

Reformat to Blood Cancer Journal using Livewrite Premium

Research Topics

Multiple Myeloma Research and Treatments Acute Myeloid Leukemia Research Lymphoma Diagnosis and Treatment Chronic Lymphocytic Leukemia Research Myeloproliferative Neoplasms: Diagnosis and Treatment Protein Degradation and Inhibitors Chronic Myeloid Leukemia Treatments Acute Lymphoblastic Leukemia research CAR-T cell therapy research Hematopoietic Stem Cell Transplantation Peptidase Inhibition and Analysis Eosinophilic Disorders and Syndromes Viral-associated cancers and disorders Immune Cell Function and Interaction Amyloidosis: Diagnosis, Treatment, Outcomes Cancer Treatment and Pharmacology Kruppel-like factors research Ubiquitin and proteasome pathways Histone Deacetylase Inhibitors Research Retinoids in leukemia and cellular processes Cancer Genomics and Diagnostics Monoclonal and Polyclonal Antibodies Research Immunodeficiency and Autoimmune Disorders CNS Lymphoma Diagnosis and Treatment Immunotherapy and Immune Responses

Related Journals

Ph
Phenomics Springer Nature
SI
Seminars in Thrombosis and Hemostasis Thieme Medical Publishers (Germany)
LC
Lung Cancer Targets and Therapy Dove Medical Press
RI
Radiology Imaging Cancer Radiological Society of North America
CR
Cancer Research American Association for Cancer Research
C&
Cancer & Metabolism BioMed Central